An end to need for systematic updates of EU risk management plans
This article was originally published in SRA
Companies with products on the EU market no longer have to update their risk management plans on the basis of a pre-agreed timetable. Instead, they need do so only when changes are made to the RMP, says the European Medicines Agency1.
You may also be interested in...
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.
Coronavirus Notebook: EMA Issues Guidance On Development Of Variant Vaccines, EU Leaders Urge Production Ramp-Up
A batch of AstraZeneca/Oxford University coronavirus vaccines has arrived in Ghana, the first country in the world to receive vaccines via the COVAX Facility.